Aquestive Therapeutics Reports Leadership Changes
Ticker: AQST · Form: 8-K · Filed: Apr 1, 2024 · CIK: 1398733
| Field | Detail |
|---|---|
| Company | Aquestive Therapeutics, Inc. (AQST) |
| Form Type | 8-K |
| Filed Date | Apr 1, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.001, $0.01 |
| Sentiment | neutral |
Sentiment: neutral
Topics: leadership-change, executive-compensation, board-of-directors
Related Tickers: AQST
TL;DR
Aquestive Therapeutics (AQST) filed an 8-K on April 1st detailing board and exec changes. Watch for new strategy.
AI Summary
Aquestive Therapeutics, Inc. filed an 8-K on April 1, 2024, reporting changes in its board of directors and executive officers, as well as updates to compensatory arrangements. The filing indicates a shift in leadership and potential adjustments to executive compensation structures.
Why It Matters
Changes in a company's board and executive team can signal strategic shifts or governance adjustments that may impact future performance and investor confidence.
Risk Assessment
Risk Level: medium — Leadership changes can introduce uncertainty regarding future strategy and operational execution.
Key Players & Entities
- Aquestive Therapeutics, Inc. (company) — Registrant
- April 1, 2024 (date) — Date of Report
- 001-38599 (company) — Commission File Number
- 30 Technology Drive Warren, NJ 07059 (company) — Principal Executive Offices Address
FAQ
What specific changes were made to the board of directors?
The filing indicates changes related to the 'Departure of Directors or Certain Officers' and 'Election of Directors', but specific names of departing or newly elected directors are not detailed in this summary section of the 8-K.
Were there any changes in executive officer positions?
Yes, the filing explicitly mentions 'Departure of Directors or Certain Officers' and 'Appointment of Certain Officers', indicating potential changes in executive roles.
What is the significance of the 'Compensatory Arrangements of Certain Officers' item?
This item suggests that the filing includes information about changes or updates to the compensation plans, agreements, or awards for specific executive officers.
When was this report filed with the SEC?
This 8-K report was filed with the SEC on April 1, 2024.
What is Aquestive Therapeutics, Inc.'s primary business?
Aquestive Therapeutics, Inc. is in the 'PHARMACEUTICAL PREPARATIONS' industry, SIC code 2834.
Filing Stats: 881 words · 4 min read · ~3 pages · Grade level 11 · Accepted 2024-04-01 08:15:15
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share AQST Nasdaq Global Market I
- $0.01 — f the Company's common stock, par value $0.01 per share (the "Common Stock"), under t
Filing Documents
- aqst-20240401.htm (8-K) — 31KB
- aqstpr4124.htm (EX-99.1) — 2KB
- aqstpr4124001.jpg (GRAPHIC) — 116KB
- aqstpr4124002.jpg (GRAPHIC) — 138KB
- aqstpr4124003.jpg (GRAPHIC) — 140KB
- aqstpr4124004.jpg (GRAPHIC) — 94KB
- 0001628280-24-013888.txt ( ) — 827KB
- aqst-20240401.xsd (EX-101.SCH) — 2KB
- aqst-20240401_lab.xml (EX-101.LAB) — 21KB
- aqst-20240401_pre.xml (EX-101.PRE) — 12KB
- aqst-20240401_htm.xml (XML) — 3KB
02
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers On April 1,2024, Aquestive Therapeutics, Inc. (the "Company") announced the appointment of Abigail L. Jenkins to the Board of Directors of the Company (the "Board"), effective April 1, 2024. Ms. Jenkins will serve as a Class II director with a term expiring on the Company's Annual Meeting of Stockholders in 2026. In connection with the appointment of Ms. Jenkins, the Board has appointed Ms. Jenkins to serve on the Nominating and Corporate Governance Committee of the Board. The Company announced the appointment of Ms. Jenkins to the Board in its April 1, 2024 press release. A copy of the press release is being filed with this Form 8-K as Exhibit 99.1. Ms. Jenkins was nominated by the Company's Nominating and Corporate Governance Committee (the "Committee") after a thorough review of all of the candidates' backgrounds, relevant experience and professional and personal reputations. The Committee conducted a formal search for nominees, with the assistance of an independent global talent advisory firm, and considered recommendations from Board members and management of the Company. The Board affirmatively determined that Ms. Jenkins will be an "independent director" under applicable rules of The Nasdaq Global Market. Ms. Jenkins will participate in the Company's non-employee director compensation program. A complete description of the Company's non-employee director compensation program is set forth in the Company's proxy statement for the 2023 Annual Meeting of Stockholders, filed with the Securities and Exchange Commission on April 28, 2023 ("Information About Nominees and Continuing Directors - Board of Directors and Committees of the Board of Directors - Director Compensation") and is incorporated herein by this reference. Pursuant to the program, upon joining the Board, Ms. Jenkins will receive 57,00
Financial Statements and Exhibits
Financial Statements and Exhibits (d)Exhibits. Exhibit Number Description 99.1 Press Release, dated April 1, 2024. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: April 1, 2024 Aquestive Therapeutics, Inc. By: /s/ A. Ernest Toth, Jr Name: A. Ernest Toth, Jr. Title: Chief Financial Officer